Konjac glucomannan polysaccharide and inulin oligosaccharide ameliorate dextran sodium sulfate-induced colitis and alterations in fecal microbiota and short-chain fatty acids in C57BL/6J mice

Follow this and additional works at: https://www.biomedicinej.com/biomedicine

Part of the Life Sciences Commons, and the Medical Sciences Commons

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation
Changchien, Chih-Hsuan; Wang, Cheng-Hsin; and Chen, Hsiao-ling (2021) "Konjac glucomannan polysaccharide and inulin oligosaccharide ameliorate dextran sodium sulfate-induced colitis and alterations in fecal microbiota and short-chain fatty acids in C57BL/6J mice," BioMedicine: Vol. 11 : Iss. 3 , Article 4.
DOI: 10.37796/2211-8039.1191

This Original Articles is brought to you for free and open access by BioMedicine. It has been accepted for inclusion in BioMedicine by an authorized editor of BioMedicine.
Konjac glucomannan polysaccharide and inulin oligosaccharide ameliorate dextran sodium sulfate-induced colitis and alterations in fecal microbiota and short-chain fatty acids in C57BL/6J mice

Chih-Hsuan Changchien¹,², Cheng-Hsin Wang ³, Hsiao-Ling Chen ⁴,⁵,*

¹ Department of Medical Laboratory Science and Biotechnology, Asia University, Taiwan
² Department of Plastic and Reconstructive Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan
³ Department of Food and Nutrition, Providence University, Taiwan
⁴ Department of Food, Nutrition and Health Biotechnology, Asia University, Taiwan
⁵ Department of Medical Research, China Medical University Hospital, China Medical University, Taiwan

Abstract

Background: Konjac glucomannan polysaccharide (KGM), inulin oligosaccharide (inulin) and their mixture has been shown to modulate the gut-associated lymphoid tissue immunity.

Aims: The present study was mainly to determine effects of a low-level (2% w/w) KGM and inulin and their combination on dextran sodium sulfate (DSS)-induced colitis. We also determine the potential mechanisms mediating these effects of dietary fibers.

Methods: C57BL/6J mice (6 weeks of age, eight per group) were randomly assigned to consume one of the following diets: control (DSS group) or control diet supplemented with 2% (w/w) of KGM (KGM group), 2% (w/w) of inulin oligosaccharide (inulin group) or KGM+Inulin (1%, w/w each (K+I group)) for 29 days, combined with the DSS drinking water (2% w/v) treatment on days 21-26. Another group served as vehicle was fed the control diet and given regular drinking water throughout the study. Fresh feces were collected on days 26-29. Mice were killed on day 30 after fasting. Segments of distal colon were processed for histological procedure. The remaining colonic tissues were processed to determine the colonic gene expressions of cytokines, tight junction proteins and antioxidant enzymes.

Results: The present study indicated that DSS resulted in colonic dysplasia, severe leukocyte infiltration and enhanced gene expressions of pro-inflammatory cytokines. All fiber treatments ameliorated these indices of colitis. DSS treatment reduced the colonic gene expressions of tight junction proteins and antioxidant enzymes, which were ameliorated or normalized with fiber supplementation. In addition, all fiber treatments prevented the DSS-induced alterations in the fecal microbiota and short-chain acid levels.

Conclusion: Supplementation of low-level, 2% (w/w), of KGM polysaccharide, inulin oligosaccharide and K+I reduced the DSS-induced colitis and mucosal barrier dysfunction, which was likely to be mediated by the prebiotic effects.

Keywords: Colitis, Dextran sulfate sodium, Konjac glucomannan, Inulin, Microbiota, Mucosal barrier

Introduction

The ulcerative colitis is an inflammatory bowel disease (IBD) that occurs in the colon [1]. Epidemiological studies found that the incidence and prevalence of IBD were the highest in western countries [2]. The reported annual incidence of ulcerative colitis was 24.3 and 19.2 per 100,000 person-years in Europe and North America, respectively [2]. The incidence is still...
arising in low-incidence areas such as Asia and developing countries [2]. The pathogenesis of IBD is multifactorial, involving mucosal barrier defects, dysregulated immune responses, genetic predisposition and environmental factors [3].

The mucosal barrier consists of mucosal layer, tight junction and microflora, which protects the body from potential pathogens [4]. The tight junctions form the continuous intercellular barrier between the intestinal epithelial cells is required to separate tissue spaces, regulate selective movement of solutes across the epithelium and maintain the mucosal barrier function [4]. The reduced expression of tight junction protein may lead to translocation of endotoxins and bacterial antigens and causes excessive inflammation in the gut-associated lymphocyte tissue [4].

The colonic mucosa is constantly challenged by the reactive oxidative substances produced from the microbiota and lumen contents [5]. An imbalanced cellular redox system of mucosa results excess reactive oxidative substance levels and subsequently causes gastrointestinal tract inflammation [5,6]. In addition, activated leukocytes during the active phase of inflammation generate reactive oxidative reactions that further impairs the mucosal barrier [7]. Therefore, oxidative stress is considered to play an important role in the mucosal damage in IBD [5]. For examples, previous studies indicated increased peroxidative products in both the ulcerative colitis mouse model and IBD patients [8,9].

Current medical treatments for IBD include corticosteroids, antibiotics, 5-aminosalicylic acid, immunomodulator and biological therapies [10]. Traditional therapy may cause side effects due to immune-suppression [11]. Therefore, the need for complementary and alternative medicine approaches for prevention and treatment of IBD is increasing [12].

Konjac glucomannan (KGM) is a viscous soluble fiber isolated from the underground tuber of Amorphophallus konjac [13]. It is composed of β-1, 4-linked D-glucose and D-mannose units joined together with branches through β-1,6-glucosyl units [13]. The KGM has been processed into various vegetarian food products commonly consumed in the Asian countries. Inulin, found in the underground tuber of chicory (Cichorium intybus), is an oligomer or polymer of β-D-fructose containing two to mostly sixty monomeric units that are linked by β-(2 → 1) glycosidic bridges [14]. The fraction of inulin with the degree of polymerization lower than 10, namely, inulin oligosaccharide, is widely used as a supplement in functional food [15]. Both KGM and inulin oligosaccharide have been shown to exert healthy bowel effects, such as to increase the colonic microbial fermentation products short-chain fatty acids and stimulate the growth of bifidobacteria and lactobacilli in animal/human studies [14,16-18]. KGM and inulin modulate the colonic antioxidant system and increased the antioxidant defense against the oxidative stress resulted from a low-fiber high-fat diet or a genotoxic carcinogen [18-20]. In addition, a previous study indicated that either KGM or inulin oligosaccharide could effectively strengthen the colonic mucosal barrier and increase the expressions of tight junction proteins occludin (a transmembrane barrier protein) and zone occludin-1 (ZO-1) (a peripheral scaffolding protein) [18]. These fibers also modulate gut immunity by increasing the colonic gene expression of IL-10, an anti-inflammatory cytokine [16]. However, effects of KGM and the combination of KGM and inulin oligosaccharide on prevention of ulcerative colitis have never been examined.

Dextran sodium sulfate (DSS) causes colonic intestinal epithelial cell injury and has been used to induce experimental colitis [21,22]. The present study was undertaken to investigate effects of KGM, inulin oligosaccharide and their mixture on the colonic inflammation, tight junction proteins, antioxidative enzymes, fecal microbiota and short-chain fatty acids in a DSS-induced colitis mouse model. In order to be applicable to humans, the level of fiber supplementation was only 2% w/w, which is equivalent to 10 g/d of normal human diet.

Methods

Animals

Male C57BL/6J mice were purchased at 5 weeks of age from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). Animals were housed in a solid-bottomed plastic cage with stainless wire bar lid and wood shavings for bedding in an animal holding room maintained on a 12-h light/dark cycle at 24 ± 1°C and 50 ± 2% humidity. All animals were allowed free access to water and food in the present study. The care and use of animals was in accordance with European Commission Directive 86/609/EEC for animal experiment [23] and the guidelines of the National Research Council [24]. All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee.

Experimental design

Mice (6 weeks of age, n = 8 per group) were randomly assigned into one of the following groups:
vehicle, DSS, KGM, inulin and K+I. The vehicle group consumed the control diet and regular drinking water. The other mice were DSS-treated groups; they were fed one of following diets: control (DSS group) or fiber-supplemented diet (2% w/w KGM (KGM group), 2% w/w inulin oligosaccharide (inulin group), 1% w/w KGM+1% w/w inulin oligosaccharide (K+I group)) for 29 days and were given 2% (w/v) DSS (molecular weight 36,000-50,000, MP Biomedicals, Santa Ana, CA, USA) in drinking water on days 21-26. The control diet was modified from AIN-93G [25]. Compositions of all experimental diets are shown in Table 1. The fiber-supplemented diets were adjusted based on the purity of konjac and inulin powder to provide 2% (w/w) dietary fiber supplementation. On days 26-29, mice were individually housed for collection of fresh feces. Mice were anaesthetized with CO2 and killed on day 30 after an 18-h fasting. Segments (0.4 cm²) of the distal colon were immediately fixed in 10% (v/v) buffered formalin for histological procedure. The remaining tissues were frozen for further analysis.

Histological evaluation of distal colon

Tissue sections (4 µm) were stained with hematoxylin and eosin. The histology of colonic mucosal layer was observed under a 200 × magnification.

Determination of gene expression

The colonic gene expressions of cytokines (TNF-α, IL-6 and IL-10), tight junction proteins (ZO-1 and occludin) and antioxidant enzymes including glutathione peroxidase 2 (Gpx2), glutathione S-transferase π (Gstπ1), catalase and superoxide dismutase (SOD) were determined using TaqMan gene expression assays (Applied Biosystems Life Technologies, Foster City, CA, USA) by the method described previously [18]. The TaqMan primer identification numbers of genes were provided in the supplementary material. The quantitative real-time polymerase chain reaction was performed at 50°C for 2 min, 95°C for 10 min, and fifty cycles at 95°C for 15 s and 60°C for 1 min. The relative gene expression of each target gene was first normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and further calculated relative to the level of the vehicle group using the comparative threshold cycle (Ct) method. The fold difference in gene expression was calculated as 2−ΔΔCt [26].

Determination of fecal short-chain fatty acids

Fecal acetate, propionate and n-butyrate were extracted using ether by the method described previously [18]. The fecal samples were injected onto a gas chromatography (GC-2014, Shimadzu, Tokyo, Japan) fitted with a glass capillary column (0.25 mm, 30 m Stabilwax-DA, Restek Corp., Bellefonte, PA, USA) and a flame ionization detector by the method described previously [18].

Quantification of fecal bacteria

Fecal bifidobacteria, lactobacilli and Clostridia were quantified by the fluorescent in situ hybridization method as described previously [18, 27-28]. A nucleic acid stain, 4′, 6-diamidino-2-phenylindole was used to quantify the total fecal bacteria. The microbial counts are expressed as log10 counts/g feces.

Statistical Analyses

Data were presented as means and standard error of means (S.E.M.) and analyzed using SPSS version 12. The body weights were analyzed using two-way ANOVA with day and treatment factors. One-way ANOVA followed by post hoc Tukey’s honestly significant difference test was used to determine variables across groups. Statistically significant was defined as P < 0.05.

Results

The body weights from the initial day of the DSS treatment (day 21) to the end of the study is shown in Fig. 1. Two-way ANOVA indicated significant effect of day (P < 0.001) and interaction between day and treatment (P = 0.045). Further post-hoc statistical analysis across groups indicated that the body weight of the DSS group was lower than the
respective level of the vehicle group on day 27 ($P = 0.004$), day 28 ($P = 0.001$) and day 29 ($P < 0.001$), respectively. The body weight of inulin group was greater ($P = 0.004$ vs DSS) than the level of DSS group on day 29. KGM and K+I did not significantly affect the body weight compared with the respective level of DSS group during days 21-29.

The cross-section histology of distal colon indicated severe dysplasia in the DSS group, which was not observed in the vehicle and fiber-supplemented groups (Fig. 2). In addition, the present study found severe leukocyte infiltration throughout the lamina propria and extending into the submucosal tissues in the DSS group, which was not observed in the vehicle and was ameliorated in fiber-supplemented groups.

The DSS treatment significantly up-regulated the colonic gene expression of TNF-$\alpha$ ($P < 0.001$ vs vehicle) and IL-6 ($P < 0.001$ vs vehicle), respectively (Fig. 3). The gene expression of TNF-$\alpha$ in the KGM, inulin or K+I was significantly lower than that in the DSS group ($P < 0.001$ for each fiber vs DSS, respectively). Similarly, the gene expressions of IL-6 in all fiber-supplemented groups were significantly lower than that in the DSS group ($P < 0.001$ for each fiber vs DSS, respectively). On the other hand, DSS treatment significantly reduced the colonic gene expression of IL-10 ($P < 0.001$ vs vehicle). The gene expression of IL-10 in the KGM, inulin and K+I group was significantly greater than the level in the DSS group, respectively ($P < 0.001$ for each fiber vs DSS, respectively).

The DSS treatment significantly down-regulated the gene expressions of tight junction proteins ZO-1 ($P < 0.001$ vs vehicle) and occludin ($P < 0.001$ vs vehicle) (Fig. 4). Supplementation of KGM, inulin and K+I up-regulated the ZO-1 gene expression, respectively ($P < 0.001$ for each fiber vs DSS, respectively). All fiber supplementations also enhanced the occludin gene expressions ($P < 0.001$ for each fiber vs DSS, respectively).

The DSS treatment significantly down-regulated the colonic gene expression of glutathione peroxidase ($P < 0.001$ vs vehicle), glutathione S-transferase ($P < 0.001$ vs vehicle), catalase ($P < 0.001$ vs vehicle) and SOD ($P < 0.001$ vs vehicle), respectively (Fig. 5).
KGM, inulin and K+I ameliorated the DSS-induced suppression of glutathione peroxidase gene expression ($P < 0.001$ vs DSS, respectively) and catalase gene expression ($P < 0.001$ vs DSS, respectively). The gene expressions of glutathione S-transferase in all fiber groups were normalized to the level in the vehicle group ($P > 0.05$ for each fiber vs vehicle, respectively), respectively. The gene expressions of SOD in all fiber groups were also similar to that in the vehicle group ($P > 0.05$ for each fiber vs vehicle, respectively).

The DSS treatment decreased the fecal lactobacilli ($P < 0.001$ vs vehicle) and bifidobacteria ($P < 0.001$ vs vehicle) concentrations (log$_{10}$ counts/g feces) and increased the Clostridia concentration ($P < 0.001$ vs vehicle) compared with the respective level in the vehicle group (Fig. 6). The fecal microbiota was normalized with all fiber treatments. However, the fecal total bacterial concentration was not affected with the DSS treatment and was similar across groups.

The DSS treatment decreased the fecal acetate, propionate, butyrate and total short-chain fatty acid concentrations compared with the respective level in the vehicle group ($P < 0.001$ vs vehicle, respectively) (Table 2). KGM, inulin and K+I increased the fecal acetate by approximately 66.0% ($P = 0.012$ vs DSS), 47.0% ($P = 0.035$ vs DSS) and 59.1% ($P = 0.028$ vs DSS), respectively, compared with the level in the DSS group. KGM, inulin and K+I increased the fecal propionate by approximately by 54.2% ($P = 0.030$ vs DSS), 75.0% ($P < 0.001$ vs DSS) and 64.6% ($P = 0.010$ vs DSS), respectively, compared with the level in the DSS group. KGM, inulin and K+I increased the fecal butyrate approximately by 1.3-fold ($P < 0.001$ vs DSS), 2.3-fold ($P < 0.001$ vs DSS) and 2-fold ($P < 0.001$ vs DSS), respectively, compared with the level in the DSS group.

Discussion

There are several unique aspects in the present study. Firstly, the DSS administered in the present study, 2% w/v, was lower than those used in previous studies, 3-8% w/v in drinking water [29-32]. The DSS-treated period in the present study was also shorter than that shown in previous studies [30,32]. Secondly, the present study determined the preventive effects of dietary fiber on colitis, instead
of being an adjunct treatment during the active phase of colitis [29-32]. Thirdly, the present study compared effects of combination of polysaccharide (KGM) and inulin oligosaccharide with single fiber source on DSS-induced colitis. We further examined the potential underlying mechanisms that mediated the anti-colitis effects of these dietary fibers.

In order to set up an optimally low DSS dose for inducing experimental colitis, we examined the outcomes of 2% (w/v) DSS water for 5 days in a pilot study. With this low-dose DSS treatment, we observed severe crypt destruction and leukocyte infiltration in the distal colon, in agreement with the those observed by other studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30]. The present study further indicated that this low-dose DSS treatment caused large increases in the colonic expression of pro-inflammatory cytokines TNF-α and IL-6, in agreement with those observed in previous studies using higher dose of DSS [29,30].

KGM, Konjac glucomannan; K+I, Konjac glucomannan + inulin oligosaccharide.

1 Data were expressed as mean values and standard error of means (n 8 per group). The differences across groups were determined using one-way ANOVA followed by post hoc Tukey’s honestly significant difference test. Mean values with unlike letters are significantly different across groups as analyzed by one-way ANOVA followed by Tukey’s honestly significant difference test (P < 0.05).
In the present study, all distributions in the cellular membrane [40-41]. In proteins and induces ZO-1 and occludin re-contribute to their anti-colitis effects. ZO-1 and occludin expression, which possibly prevented the DSS-induced down-regulation of that KGM and inulin oligosaccharide could bene-ferred by a leaky mucosal layer [4]. In this study, the microbiota. Therefore, the anti-colitis effects of sol-uble fiber treatments in the present study may be mediated by their prebiotic roles [39].

Inflammatory bowel disease is likely to be trig-gered by a leaky mucosal layer [4]. In this study, the DSS treatment down-regulated the gene expres-sions of tight junction proteins, which suggested that DSS might damage the mucosal barrier function. Soluble fibers have been shown to up-regulate the ZO-1 and occludin expressions in the wild-type [18] and the occludin in the CD4+CD62L+T cell transfer model of colitis mice [34]. In accordance with previous studies, the present results indicated that KGM and inulin oligosaccharide could bene-ficially prevent the DSS-induced down-regulation of ZO-1 and occludin expression, which possibly contribute to their anti-colitis effects.

Previous in vitro studies have suggested that the butyrate is vital for normal colonocyte proliferation and increases the transcription of tight junction proteins and induces ZO-1 and occludin re-distributions in the cellular membrane [40-41]. In the present study, all fiber treatments significantly enhanced the fecal butyrate level. Therefore, we suggested that the butyrate derived from the diet-ary fibers might prevent the DSS-induced colonic mucosal dysplasia and the mucosal layer damage.

The present study indicated reduced expressions of colonic antioxidant enzymes in the DSS group, which suggested an impaired colonic antioxidant defense system in this colitis model. We have previ-ously reported that 2% (w/w) KGM, inulin oligo-saccharide and K+I up-regulated the expressions of colonic antioxidant enzymes [18]. The present study further indicated that these dietary fibers did not just ameliorate the DSS-induced down-regulation in colonic antioxidant enzymes, but also almost normalized the expressions of glutathione S-transferase and SOD to the level of the vehicle group. Therefore, the present study suggested that KGM, inulin oligosaccharide and K+I pretreatment strengthened the colonic antioxidant defense system against the challenge caused by DSS.

In conclusion, the present study suggests that a low-level, 2% (w/w), of KGM polysaccharide, inulin oligosaccharide and the fiber mixture may prevent the DSS-induced colitis, which is likely to be asso-ciated with the prebiotic role of these fibers.  

Acknowledgments

Authors would like to thank Ms. Yi-Chun Han for her assistance in the animal experiment.

Financial support

This study was supported by 101-2320-B-040-018-MY2, 103-2320-B-468-005 from Ministry of Science and Technology (Taiwan), CMU105-ASIA-15, CMU106-ASIA-16, and Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan.

Conflict of interest

All authors have no relevant financial interests related to the material in the manuscript.

References

1 Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807–16.
2 Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.
3 Ungaro R, Mehandru S, Allen PB, Laurent PB, Jean-Chenoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.
4 Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019;68:1516–26.
5 Seri DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003;24:353–62.
6 Babb CS. Free radicals and the etiology of colon cancer. Free Radic Biol Med 1990;8:191–200.
7 Biasi F, Leonardiuzzi G, Oiteza PI, Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal 2013;19:1711–47.
8 Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 2007;22:1846–51.
9 Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 2003;201:28–36.
10 Clarke JO, Mullin GE. A review of complementary and alternative approaches to immunomodulation. Nutr Clin Pract 2008;23:49–62.

11 Toruner M, Loftus EVJ, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.

12 Mijan MA, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterology 2018;24:2673–85.

13 Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995;49(Suppl 3):S190–7.

14 Pool-Zobel B, van Loo J, Rowland I, Roberfroid MB. Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Br J Nutr 2002;87(Suppl 2): S273–81.

15 Sabater-Molina M, Larqué E, Torrella F, Zamora S. Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem 2009;65:315–28.

16 Chen HL, Lin YM, Wang YC. Comparative effects of cellulose and soluble fibers (pectin, konjac glucomannan, inulin) on fecal water toxicity toward Caco-2 cells, fecal bacteria enzymes, bile acid, and short-chain fatty acids. J Agr Food Chem 2010;58:12777–81.

17 Chen H-L, Cheng H-C, Wu W-T, Liu Y-J, Liu S-Y. Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults—a placebo-controlled, diet-controlled trial. J Am Coll Nutr 2008;27:102–8.

18 Changchien CH, Han YC, Chen HL. Konjac glucomannan polysaccharide and inulin oligosaccharide enhance the colonic mucosal barrier function and modulate gut-associated lymphoid tissue immunity in C57BL/6j mice. Br J Nutr 2020;123:319–27.

19 Wu WT, Chen HL. Konjac glucomannan and inulin systemically modulated antioxidant defense in rats fed a high-fat fiber-free diet. J Agric Food Chem 2011;59:9194–200.

20 Wu WT, Yang LC, Chen HL. Effects of konjac glucomannan, inulin and cellulose on acute colonic responses to genotoxic azosymethane. Food Chem 2014;140:30–10.

21 Koetzner L, Grover G, Boulet J, Jacoby HI. Plant-derived polysaccharide supplements inhibit dextran-sulfate-sodium-induced colitis in the rat. Dig Dis Sci 2010;55:1278–85.

22 Eichele DD, Kharbanda KK. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterology 2017;23:6016–29.

23 European Council. European Commission Directive 86/609/EEC for animal experiment. http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm. [Accessed 6 January 2021]. Updated May 15, 2020.

24 National Research Council (US). Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals 8th ed. Washington, DC: National Academies Press; 2011.

25 Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1399–51.

26 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−(Delta Delta C(T)) Method. Methods 2001;25:402–8.

27 Wang RF, Cao VW, Cerniglia CE. PCR detection and quantification of predominant anaerobic bacteria in human and animal fecal samples. Appl Environ Microbiol 1996;2:1242–7.

28 Nagahama M, Nagayasu K, Kobayashi K, Sakurai J. Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells. Infect Immun 2002;70:1909–14.

29 Naito Y, Takagi T, Katada K, Uchiyama K, Kuroda M, Kokura S, et al. Partially hydrolyzed guar gum down-regulates colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. J Nutr Biochem 2006;17:402–9.

30 Lee H, Son YS, Lee MO, Ryu JW, Park K, Kwon O, et al. Low-dose interleukin-2 alleviates dextran sodium sulfate-induced colitis in mice by recovering intestinal integrity and inhibiting AKT-dependent pathways. Theranostics 2020;10:5048–63.

31 Dai C, Zheng C-Q, Meng F-J, Zhou Z, Sang LX, Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3K/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol Cell Biochem 2013;374:1–11.

32 Winkler J, Butler R, Symonds E. Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis. Dig Dis Sci 2007;52:52–8.

33 Videla S, Vilaseca J, Antolin M, García-Lafuente A, Guerrer F, Crespo E, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001;96:1486–93.

34 Captián-Cañadas F, Ocon B, Aranda CJ, Anzola A, Suárez MD, Zarzuelo A, et al. Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L− T cell transfer model of colitis in C57BL/6j mice. Eur J Nutr 2016;55:1445–54.

35 Gourbeyre P, Denery S, Bodinier M. Probiotics, prebiotics, and synbiotics: impact on the gut immune system and allergic reactions. J Leukoc Biol 2011;89:685–95.

36 Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017;9:1021. https://doi.org/10.3390/nu9091021.

37 Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, et al. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology 2018;155:36–52.

38 Osman N, Adawi D, Molin G, Ahrne S, Berggren A, An-Ca Dong J, et al. Fructooligosaccharides exert anti-inflammatory activity on CD16+ CD62L+ T cell transfer model of colitis in C57BL/6j mice. Eur J Nutr 2016;55:1445–54.

39 Bordin M, D’Atri F, Guillomet L, Citi S. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. Mol Cancer Res 2004;2:692–701.

40 Bordin M, D’Atri F, Guillomet L, Citi S. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins Claudin-1 transcription. Dig Dis Sci 2012;57:3126–35.